For et lille antal patienter med astma var hyppigheden af alvorlig infektion højere hos Kineret- behandlede patienter (4, 5%) sammenlignet med placebo- behandlede patienter (0%).
For a small number of patients with asthma, the incidence of serious infection was higher in Kineret-treated patients (4.5%) vs. placebo-treated patients (0%).